uniQure NV News

UniQure Shares Rise After US FDA Grants Regenerative Medicine Advanced Designation for Huntington's Treatment

uniQure (QURE) shares rose 8% in recent Monday trading after the company obtained the regenerative medicine advanced therapy designation from the US Food and Drug Administration for AMT-130 to treat H

MT NewswiresJun 3 10:59 ET

UniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington's Disease

~ Designation based on 24-month interim Phase I/II clinical data for AMT-130 announced in December 2023 ~ ~ AMT-130 is the first therapeutic candidate to receive RMAT Designation for Huntington's disease ~ ~ Receiving

GlobeNewswireJun 3 07:05 ET

UniQure N.V. (NASDAQ:QURE) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

It's been a good week for uniQure N.V. (NASDAQ:QURE) shareholders, because the company has just released its latest quarterly results, and the shares gained 4.5% to US$4.89. Revenues of US$8.5m

Simply Wall StMay 9 06:16 ET

Stifel Nicolaus Sticks to Its Buy Rating for UniQure (QURE)

TipRanksMay 8 22:10 ET

UniQure Price Target Maintained With a $25.00/Share by HC Wainwright & Co.

UniQure Price Target Maintained With a $25.00/Share by HC Wainwright & Co.

Dow JonesMay 8 15:17 ET

Express News | HC Wainwright & Co. Reiterates Buy on UniQure, Maintains $25 Price Target

BenzingaMay 8 15:07 ET

Mizuho Adjusts UniQure's Price Target to $6 From $7, Keeps Neutral Rating

Mizuho Adjusts uniQure's Price Target to $6 From $7, Keeps Neutral Rating.

MT NewswiresMay 8 10:13 ET

UniQure Price Target Cut to $6.00/Share From $7.00 by Mizuho

UniQure Price Target Cut to $6.00/Share From $7.00 by Mizuho

Dow JonesMay 8 08:20 ET

Express News | Mizuho Maintains Neutral on UniQure, Lowers Price Target to $6

BenzingaMay 8 08:10 ET

Express News | Uniqure NV : Mizuho Cuts Target Price to $6 From $7

ReutersMay 7 23:22 ET

uniQure NV | 10-Q: Quarterly report

SEC announcementMay 7 07:59 ET · Announcements

Earnings Flash (QURE) UNIQURE Reports Q1 Revenue $8.5M

07:27 AM EDT, 05/07/2024 (MT Newswires) -- Earnings Flash (QURE) UNIQURE Reports Q1 Revenue $8.5M

MT NewswiresMay 7 07:27 ET

UniQure Expects Cash, Cash Equivalents and Investment Securities Will Fund Ops Into the 2Q of 2027 >QURE

UniQure Expects Cash, Cash Equivalents and Investment Securities Will Fund Ops Into the 2Q of 2027 >QURE

Dow JonesMay 7 07:20 ET

UniQure Comprehensive Review of Ops and Options to Reduce Expenses Underway and Expected to Be Completed in Mid-2024 >QURE

UniQure Comprehensive Review of Ops and Options to Reduce Expenses Underway and Expected to Be Completed in Mid-2024 >QURE

Dow JonesMay 7 07:20 ET

Press Release: UniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress On track to initiate FDA interaction regarding AMT-130 in second quarter of 2024 and provide a clinical u

Dow JonesMay 7 07:05 ET

UniQure 1Q Loss/Shr $1.36 >QURE

UniQure 1Q Loss/Shr $1.36 >QURE

Dow JonesMay 7 07:05 ET

UBS Lowers UniQure's Price Target to $27 From $38, Maintains Buy Rating

UBS Lowers UniQure's Price Target to $27 From $38, Maintains Buy Rating.

MT NewswiresApr 2 11:50 ET

Kyowa Kirin's Rare Disease Therapy Becomes World's Most Expensive Drug

Seeking AlphaMar 20 12:11 ET

13 Best Biotech Stocks To Buy Under $20

Yahoo FinanceMar 13 07:07 ET

AMD To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. B of A Sec

BenzingaMar 4 07:56 ET